Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/5/453 |
| _version_ | 1797535394756034560 |
|---|---|
| author | Aline Baldo Amaya Leunda Nicolas Willemarck Katia Pauwels |
| author_facet | Aline Baldo Amaya Leunda Nicolas Willemarck Katia Pauwels |
| author_sort | Aline Baldo |
| collection | DOAJ |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used for the development of COVID-19 vaccine candidates: recombinant viral vectors, protein-based vaccines, nucleic acid-based vaccines, and inactivated/attenuated virus. Recombinant viral vector vaccine candidates represent a significant part of those vaccine candidates in clinical development, with two already authorised for use in the European Union and one currently under rolling review by the European Medicines Agency (EMA). Since recombinant viral vector vaccine candidates are considered as genetically modified organisms (GMOs), their regulatory oversight includes besides an assessment of their quality, safety and efficacy, also an environmental risk assessment (ERA). The present article highlights the main characteristics of recombinant viral vector vaccine (candidates) against SARS-CoV-2 in the pipeline and discusses their features from an environmental risk point of view. |
| first_indexed | 2024-03-10T11:43:53Z |
| format | Article |
| id | doaj.art-ee671045f0034594a853f77f72ba1c17 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T11:43:53Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-ee671045f0034594a853f77f72ba1c172023-11-21T18:18:21ZengMDPI AGVaccines2076-393X2021-05-019545310.3390/vaccines9050453Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2Aline Baldo0Amaya Leunda1Nicolas Willemarck2Katia Pauwels3Sciensano, Service Biosafety and Biotechnology, Rue Juliette Wytsmanstraat 14, B-1050 Brussels, BelgiumSciensano, Service Biosafety and Biotechnology, Rue Juliette Wytsmanstraat 14, B-1050 Brussels, BelgiumSciensano, Service Biosafety and Biotechnology, Rue Juliette Wytsmanstraat 14, B-1050 Brussels, BelgiumSciensano, Service Biosafety and Biotechnology, Rue Juliette Wytsmanstraat 14, B-1050 Brussels, BelgiumSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used for the development of COVID-19 vaccine candidates: recombinant viral vectors, protein-based vaccines, nucleic acid-based vaccines, and inactivated/attenuated virus. Recombinant viral vector vaccine candidates represent a significant part of those vaccine candidates in clinical development, with two already authorised for use in the European Union and one currently under rolling review by the European Medicines Agency (EMA). Since recombinant viral vector vaccine candidates are considered as genetically modified organisms (GMOs), their regulatory oversight includes besides an assessment of their quality, safety and efficacy, also an environmental risk assessment (ERA). The present article highlights the main characteristics of recombinant viral vector vaccine (candidates) against SARS-CoV-2 in the pipeline and discusses their features from an environmental risk point of view.https://www.mdpi.com/2076-393X/9/5/453SARS-CoV-2COVID-19recombinant viral vector vaccinesenvironmental risk assessmentvaccinationbiosafety |
| spellingShingle | Aline Baldo Amaya Leunda Nicolas Willemarck Katia Pauwels Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2 Vaccines SARS-CoV-2 COVID-19 recombinant viral vector vaccines environmental risk assessment vaccination biosafety |
| title | Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2 |
| title_full | Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2 |
| title_fullStr | Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2 |
| title_full_unstemmed | Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2 |
| title_short | Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2 |
| title_sort | environmental risk assessment of recombinant viral vector vaccines against sars cov 2 |
| topic | SARS-CoV-2 COVID-19 recombinant viral vector vaccines environmental risk assessment vaccination biosafety |
| url | https://www.mdpi.com/2076-393X/9/5/453 |
| work_keys_str_mv | AT alinebaldo environmentalriskassessmentofrecombinantviralvectorvaccinesagainstsarscov2 AT amayaleunda environmentalriskassessmentofrecombinantviralvectorvaccinesagainstsarscov2 AT nicolaswillemarck environmentalriskassessmentofrecombinantviralvectorvaccinesagainstsarscov2 AT katiapauwels environmentalriskassessmentofrecombinantviralvectorvaccinesagainstsarscov2 |